Respiratory Syncytial Virus Antigens and Antibodies for Vaccine Development
Respiratory syncytial virus (RSV) is a very contagious virus that causes a respiratory tract infection, affecting 64 million people per year worldwide. Currently, there is no licensed vaccine to prevent RSV infections. The only FDA approved treatment option is a humanized monoclonal antibody (IgG) against the RSV fusion protein, known as palivizumab. Creative Diagnostics has…
Read More “Respiratory Syncytial Virus Antigens and Antibodies for Vaccine Development” »